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Abstract
Background: The secretory basic amino acid-specific proprotein convertases (PCs) have often
been associated with cancer/metastasis. By controlling the cleavage of cancer-associated proteins,
PCs play key roles in multiple steps of cancer development. Most analyses of the implication of PCs
in cancer/metastasis relied on the use of in vitro overexpression systems or inhibitors that can affect
more than one PC. Aside from the role of furin in salivary gland tumorigenesis, no other in vivo
genetic model of PC-knockout was reported in relation to cancer development.
Results: Since PC5/6 is highly expressed in the small intestine, the present study examined its in
vivo role in intestinal tumorigenesis. Analysis of human intestinal tumors at various stages showed
a systematic down-regulation of PC5/6 expression. Since gene inactivation of PC5/6 leads to
lethality at birth, we generated mice lacking PC5/6 in enterocytes and analyzed the impact of the
presence or absence of this PC in the mouse ApcMin/+ model that develops numerous
adenocarcinomas along the intestinal tract. This resulted in viable mice with almost no expression
of PC5/6 in small intestine, but with no overt phenotype. The data showed that by themselves
ApcMin/+ tumors express lower levels of PC5/6 mRNA, and that the lack of PC5/6 in enterocytes
results in a significantly higher tumor number in the duodenum, with a similar trend in other
intestinal segments. Finally, the absence of PC5/6 is also associated with a premature mortality of
ApcMin/+ mice.
Conclusion: Overall, these data suggest that intestinal PC5/6 is protective towards tumorigenesis,
especially in mouse duodenum, and possibly in human colon.
Background
Nine secretory proprotein convertases (PCs) of the subtili-
sin/kexin type (genes PCSK1 to PCSK9) were identified in
mammals and are known as: PC1/3, PC2, furin, PC4,
PC5/6, PACE4, PC7, SKI-1/S1P and PCSK9 [1,2]. The first
7 convertases cleave secretory precursor proteins at single
or paired basic residues [2], whereas SKI-1/S1P [3] and
PCSK9 [4] do not require a basic residue at the cleavage
site. The basic amino acid (aa)-specific convertases proc-
ess precursors of growth factors, receptors, polypeptide
hormones, adhesion molecules, proteases, as well as cell
surface proteins of infectious viruses and bacteria [2]. In
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endothelial and lipoprotein lipases [5], PCSK9 [6] and N-
cadherin (Maret D. et al., submitted).
Overexpression of PC5/6, PACE4 and furin revealed that
these proteinases can often cleave the same precursors,
indicating a functional redundancy [6-12]. Evidence for in
vivo redundancy was provided by furin inactivation in the
liver, which revealed that most of the precursors analyzed
were still processed, although to a lesser extent, in the
absence of this ubiquitous convertase [13]. In contrast, in
vivo studies demonstrated that in a spatio-temporal man-
ner furin can uniquely process the Ac45 subunit of the
vacuolar type H+-ATPase in pancreatic β-cells [14] and
PC5/6 the TGFβ-like growth and differentiation factor
Gdf11 in the developing embryo [15,16].
Various precursors cleaved by overexpressed furin, PC5/6,
PACE4 and PC7 have been previously implicated in can-
cer and associated metastatic processes [17-19]. A correla-
tion between the mRNA levels of some of these PCs and
the degree of tumorigenicity has been reported [9,18-27].
Furthermore, injection/implantation of various cell lines
expressing PC inhibitors, such as the antitrypsin derivative
α1-PDX [9,12,20,24,27,28] or the inhibitory prodomain
of PCs [26] suggested a critical role of the PCs in tumor
growth and/or metastasis.
The convertase PC5/6 (previously known as PC5 or PC6)
was characterized in 1993 and shown to be composed of
two differentially spliced isoforms, a short 915 aa soluble
PC5/6A [29], and a long membrane-bound 1877 aa PC5/
6B [30]. In adult rodents, PC5/6 exhibits a wide tissue dis-
tribution [29], which in mice when analyzed by quantita-
tive PCR (QPCR) revealed that the adrenal cortex and
small intestine are the richest sources of PC5/6A and PC5/
6B, respectively [31]. However, the function of PC5/6 in
these tissues has not been addressed. PC5/6 can bind cell
surface heparan sulfate proteoglycans and tissue inhibi-
tors of metalloproteases via its C-terminal Cys-rich
domain [32]. It also seems to differ from the other conver-
tases in that it can get activated at the cell surface [1,33].
Knockout of the PC5/6 gene (Pcsk5) revealed that Pcsk5-/-
animals die at birth due to multiple malformations,
including defects in antero-posterior patterning and heart
formation [15,16]. Defective specification of segment
identity, which leads to an increased number of thoracic
and lumbar vertebrae and lack of tail, is likely due to the
absence of processing of Gdf11 [15,16,34]. No obvious
malformations were seen in the small intestine of Pcsk5-/-
embryos [15].
The specific role of PC5/6 in tumorigenesis/metastasis has
not yet been investigated. PC5/6 expression was not
detected in human breast, and generally not induced in
breast cancer since it was present in only 2/30 tumors
[35]. In contrast, its mRNA levels seem to correlate with
tumor aggressiveness of head and neck- and lung tumor-
derived cell lines [18], suggesting that PC5/6 may play a
different role in metastasis compared to tumor growth.
Whether this is related to its ability to process adhesion
molecules [36], including the α-chain of various integrins
[7,37] and N-cadherin (Maret D. et al., submitted) is not yet
clear.
Colorectal cancer is the third most common form of can-
cer in the Western world. As a mouse model for this
pathology, we used the ApcMin/+ strain that harbors a het-
erozygote Min (multiple intestinal neoplasia) mutation in
the Apc (adenomatous polyposis coli) gene. These mice spon-
taneously develop polyps all along the small intestine
[38,39]. In order to assess the role of PC5/6 in intestinal
tumorigenesis, we generated PC5/6 intestine-specific
knockout mice (iKO) and crossed them with ApcMin/+
mice. Our data show that mice carrying the Min mutation
but lacking PC5/6 tend to exhibit a higher tumor number




Tg(Vil-cre) mice (stock number 004586) [40] and ApcMin/
+ mice (stock number 002020) [39] were from The Jack-
son Laboratory. Conditional knockout mice, in which the
proximal promoter and exon 1 of Pcsk5 were flanked with
loxP sites (Pcsk5flox/flox) [15], were crossed with Tg(Vil-cre)
mice that express Cre under the control of the villin pro-
moter. After two generations,Pcsk5flox/flox mice carrying
(intestinal KO; iKO) or not (wild type; WT) one copy of
the transgene were obtained and further intercrossed,
yielding the F4 progeny used in this study, which exhibits
a mixed background consisting of ~ 70% C57BL/6; 25%
129Sv and less than 5% SJL. When expressed, Cre leads to
the recombination of the two loxP sites present in Pcsk5,
resulting in the excision of ~ 3 kb of DNA including exon
1 (Δ1 alleles) and thereby gene inactivation.
Tumor scoring in mouse intestine
Four month old mice were sacrificed by CO2 asphyxia-
tion, and the whole intestine was immediately removed
and rinsed with ice-cold PBS. The intestine was divided
into duodenum, jejunum, ileum and colon. All sections
were carefully split longitudinally, fixed in 8% parafor-
maldehyde, stained with 8% methylene blue and the
tumors were counted under a binocular microscope.
Quantitative RT-PCR
Tissue samples were dissected from PBS-rinsed intestine.
Total RNA was extracted using Trizol reagent (Invitrogen),
as recommended by the manufacturer. Typically, 250 ng
of total RNA were used for cDNA synthesis in a total vol-
ume of 20 μL using SuperScript II reverse transcriptase, 25Page 2 of 9
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phosphates, and 40 U of RNaseOUT, all products from
Life Technologies, and used according to the recommen-
dations of the manufacturer. cDNAs of human adenocar-
cinomas were purchased from Origene. The quantitative
PCR (QPCR) was performed as previously described [41].
Specific primers (Table 1) were used for the simultaneous
amplification of the normalizing cDNA for ribosomal
protein S14 (human) or S16 (mouse), and the gene of
interest.
In situ hybridization
Mouse cRNA probes corresponding to the coding region
for aa 20 to 348 of PC5/6 were synthesized using 35S-UTP
and 35S-CTP (>1,000 Ci/mmol; Amersham Bioscience,
Piscataway, NJ). Cryosections (8-10 μm) were fixed for 1
hour in 4% formaldehyde and hybridized overnight at
55°C as previously described [42]. For autoradiography,
the sections were dipped in photographic emulsion (NTB-
2, Kodak, Rochester, NY), exposed for 6-12 days, and
developed in D19 solution (Kodak).
PCNA immunohistochemistry
Tissues were fixed overnight in 4% paraformaldehyde at
4°C and embedded in paraffin. Proliferation cell nuclear
antigen (PCNA) was visualized in sections of 6 μm thick-
ness by incubation with a mouse antibody (1:50; Vector
laboratories, Burlingame, CA) and a biotin-labeled sec-
ondary antibody (PerkinElmer, Boston, MA), and revela-
tion with the Vectastain kit (Vector laboratories). Sections
were also counterstained with hematoxylin and eosin.
Results
Expression of PC5/6 is lower in intestinal tumors versus 
adjacent normal tissues
Mining cancer gene expression database http://
www.oncomine.org revealed that PC5/6 expression was
significantly reduced in 7 out of 10 tumor types (P <
0.0001); [see Additional file 1: figure S1]. Since PC5/6
expression is highest in the adult small intestine [29,31],
and as no data were available for intestinal cancers, PC5/
6 mRNA levels were analyzed by QPCR in 22 human
colon tumors at stages I, II, III or IV and compared to
those of their match-paired normal adjacent tissue (Figure
1A). PC5/6 expression was on average ~ 7.6-fold lower in
these human tumors. To assess whether PC5/6 was simi-
larly regulated in mouse, we used the ApcMin/+ mice, which
spontaneously develop numerous tumors in the small
intestine due to the heterozygote mutation Min in the Apc
gene. This mutation was originally discovered in patients
suffering from familial adenomatous polyposis and fre-
quently found in sporadic colorectal cancers [38,39]. Apc-
Min/+-induced tumors in the mouse small intestine
constitute a good model for colonic tumorigenesis in
human. We first quantified the expression levels of furin,
PC5/6, PACE4 and PC7, which transit through the consti-
tutive secretory pathway and cleave their substrates after
basic residues [2]. While PACE4 and PC7 did not show
any significant change, furin and PC5/6 mRNA levels were
on average ~ 1.5-fold higher (P = 0.003) and lower (P =
0.0008), respectively (Figure 1B). Closer analysis of the
duodenum-, jejunum- and ileum-associated tumors versus
their adjacent normal tissues revealed a 1.9-, 1.2- and 1.4-
fold higher furin levels, respectively, and a 2-, 1.7- and
1.1-fold lower PC5/6 expression, respectively (Figure 1C).
Using specific primers, we showed that this lower level
primarily affected PC5/6B transcripts [see Additional file
22: figure S2], which dominate in intestine [31]. The
above data thus indicated that PC5/6 is down-regulated in
many tumor types, including intestinal ones, and that in
the latter furin undergoes an opposite up-regulation. Both
PC5/6 and furin exhibited the greatest changes in the duo-
denum. These data prompted us to verify if intestinal tum-
origenesis was favored in absence of PC5/6.
Table 1: Sequences of primers used for QPCR
Assessed mRNA Forward Primer Reverse Primer
human PC5AB ACTCTTCAGAGGGTGGCTA GCTGGAACAGTTCTTGAATC
mouse PC5AB TGACCACTCTTCAGAGAATGGATAC GAGATACCCACTAGGGCAGC
mouse PC5A AGGATTCAAGAACTGTTCCA AGCATACAGAAGCCTCCTT
mouse PC5B GCAATGCCTCCCACTCCC TGCTCGTAAAACTCAGCCTCC
mouse Furin CATGACTACTCTGCTGATGG GAACGAGAGTGAACTTGGTC
Cre ATGATCCGAATAACTACCTG ACAATATTTACATTGGTCCAG
human S14 GGCAGACCGAGATGAATCCTCA CAGGTCCAGGGGTCTTGGTCC
mouse S16 GCTACCAGGGCCTTTGAGATG AGGAGCGATTTGCTGGTGTGGPage 3 of 9
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To explore the in vivo role of PC5/6 in intestinal tumor for-
mation, we specifically inactivated its gene in enterocytes
using a loxP/Cre system. Pcsk5flox/flox mice were bred to
Tg(Vil-cre) mice that expressed the Cre recombinase
under the direction of the villin promoter, specifically
expressed in enterocytes [40]. Pcsk5flox/flox mice carrying
one copy of the transgene (iKO; Tg+/0) or none (WT; Tg0/
0) were generated. To verify that the presence of the trans-
gene resulted in an efficient inactivation of Pcsk5 in ente-
rocytes, we analyzed PC5/6 mRNA levels using QPCR and
in situ hybridization in 3 mice of each genotype. Duode-
num, jejunum, ileum and colon sections were dissected
for further RNA extraction and tissue sectioning. Cre
expression under the villin promoter in iKO mice was
highest in duodenum and progressively diminished along
the intestinal tract to reach ~ 25% of the duodenum level
in the distal colon (Figure 2A). In WT mice, PC5/6 expres-
sion is elevated in the small intestine, especially in the
duodenum, as compared to colon (Figure 2B). Indicative
of the Cre efficiency all along the intestine, the absolute
numbers of PC5/6 mRNA remaining in all sections of iKO
intestine were very similar: 1.6 to 3.1 PC5/6 mRNA/1000
S16 mRNA. Furthermore, in situ hybridization with a
PC5/6 cRNA probe confirmed that PC5/6 transcripts were
strongly reduced in iKO intestinal enterocytes (Figure 3).
The low residual expression observed by QPCR (Figure
2B) and in situ hybridization labeling suggest that in the
small intestine PC5/6 is mainly expressed in enterocytes,
but to a much less extent expressed in other cell types all
along the intestine. Finally, the morphology and prolifer-
ation of enterocytes was assessed by immunohistochemis-
try. No gross malformation was observed and labeling
with PCNA, a marker for proliferation, was not signifi-
cantly different between the two genotypes [see Addi-
tional file 3: figure S3].
PC5/6 deficiency has a significant impact on Min 
mutation-induced tumorigenesis in the duodenum
Intercrossing of [Pcsk5flox/flox Tg(Vil-cre)+/0] with [Pcsk5flox/
flox ApcMin/+] generates 25% mice that carry only the Min
mutation (WTMin), and exhibit normal levels of PC5/6 in
intestine. Another 25% of these mice carry both the Min
mutation and the Cre transgene (iKOMin), and lack PC5/6
expression in enterocytes. Duodenum, jejunum and
ileum from 11 WTMin mice and 17 iKOMin mice were dis-
sected out, opened longitudinally and stained with meth-
ylene blue (Figure 4A). All the tumors, including those
exceeding 2 mm in diameter, were counted along the
entire section of each tissue. The average tumor density
(tumors/cm) in the duodenum of iKOMin mice was signif-
icantly higher than that in WTMin mice (P = 0.01; Figure
4B). In iKO mice, the duodenum is the tissue in which the
PC5/6 drop was the most drastic (Figure 2). However,
although this trend was observed in other intestinal sec-
Decreased expression of PC5/6 in intestinal tumors versus adjac nt normal ti suesFigure 1
Decreased expression of PC5/6 in intestinal tumors 
versus adjacent normal tissues. (A) RNA samples from 
human colonic adenocarcinomas (stage I, II, III or IV) and 
their adjacent normal tissues were submitted to QPCR anal-
ysis (n = 6, 7, 7 and 2 for stages I, II, III and IV, respectively). 
(B) In each small intestine section (duodenum, jejunum and 
ileum) from 3 ApcMin/+ mice, 2 tumors and their adjacent nor-
mal tissue (6 couples/section) were dissected and assessed 
for the expression levels of furin, PC5/6, PACE4 and PC7 by 
QPCR. Normalized expression values are shown for the 18 
samples of normal tissues and 18 samples of tumors. (C) 
Expression of PC5/6 and furin in tumors was also analyzed by 
intestinal section. All mRNA levels in tumors were normal-
ized to their respective normal tissue expression and have 
been log2 transformed, with the median of the total 18 sam-
ples set to 0. *, P < 0.05; **, P < 0.005; ***, P < 5.10-11 (Stu-
dent's t test).Page 4 of 9
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number of tumors in iKOMin mice, 58 versus 46 in WT
mice, was not significantly higher (Figure 4C). In addi-
tion, the numbers of large tumors (>2 mm; Figure 4C)
were very similar in both cases. Overall, this analysis indi-
cates that only in duodenum does the loss of PC5/6 signif-
icantly enhance intestinal tumorigenesis.
PC5/6 deficiency shortens the half-life of ApcMin/+ mice
Apc Min/+ mice having a pure C57BL/6 background were
reported to die by 120 days of age [38,39], likely due to
severe chronic anemia [38]. In this study, WTMin mice
exhibited a longer half-life of 180 days, possibly due to
their mixed background (see Methods). However, in the
absence of intestinal PC5/6, this half-life was significantly
shortened to 140 days (P = 0.03; Figure 5), suggesting that
PC5/6 exerts a protective effect on these mice. ApcMin/+
mice develop anemia with a severity that seems to depend
on the density of intestinal adenomas [38]. Considering
that iKOMin mice had a trend for higher numbers of
tumors, especially in the duodenum, premature death of
iKOMin mice could be the result of more severe chronic
anemia [38], which could be exacerbated by multiple
hemorrhages, as observed in the liver and subcutaneously
in PC5/6 knockout mice [15]. In the future, it may be val-
uable to examine whether PC5/6 levels correlate with the
survival rate, or intestinal bleeding/anemia of patients
that suffer from colorectal carcinomas.
Discussion
The use of general PC-inhibitors such as α1-PDX or pro-
furin revealed that PC-inhibition decrease tumorigenesis
and metastasis in nude mice [9,12,20,26], but enhance
metastasis in immunosuppressed newborn rats [43]. This
is probably due to the ability of overexpressed PC-inhibi-
tors to block the activity of more than one convertase [44],
which may exert opposite regulating effects and modulate
multiple processes. Thus, mice lacking a specific conver-
tase should represent a more powerful tool to assess the
specific function of a single convertase. Of all the PC
knockout mice, those lacking furin [45] and PC5/6
[15,16] exhibit a fully penetrant embryonic lethal pheno-
type, precluding their use in adult mouse studies. Tissue-
specific knockouts thus provide a potential approach to
test their effect in cancer/metastasis. So far, the in vivo role
of a specific PC in tumorigenesis was only investigated in
mice lacking furin in salivary glands among other tissues
[46]. In these mice, the simultaneous inactivation of furin
and overexpression of the PLAG1 transcription factor,
which induced the formation of adenomas in salivary
glands, showed that the absence of furin delayed tumori-
genesis [46], suggesting a pro-tumorigenic effect of furin.
The present study is the first attempt to assess the role of
PC5/6 in cancer development using knockout mice. The
impact of PC5/6 has been analyzed here exclusively in
vivo, using the ApcMin/+ intestinal tumorigenesis model. We
first evaluated PC5/6 mRNA levels in intestinal tumors
versus normal tissue obtained from colon cancer patients
(Figure 1A) or ApcMin/+ mice (Figure 1B and 1C), and
showed that PC5/6 is systematically down-regulated in
intestinal tumors. To probe the role of PC5/6 in tumori-
genesis, we compared the number and size of intestinal
tumors in ApcMin/+ mice lacking or not PC5/6 (Figure 4).
The data showed a trend for an enhanced tumorigenesis
in PC5/6-deficient mice, reaching significance only in the
duodenum (Figure 4B) where PC5/6 is primarily
expressed (Figure 2A), suggesting that it may exert specific
functions therein. This result was unexpected in view of
the reported reduced tumorigenesis by general PC-inhibi-
tors [18,20-22].
Efficient inactivation of Pcsk5 in iKO miceFigure 2
Efficient inactivation of Pcsk5 in iKO mice. (A) Cre 
expression was assessed in intestinal segments from 3 iKO 
mice. Expression values were normalized to that of S16 
mRNA. (B) PC5/6 expression was quantified in each intesti-
nal segment from 3 WT and 3 iKO mice and normalized to 
that of S16. Error bars represent SEM.Page 5 of 9
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Detection of PC5/6 transcripts in WT and iKO intestine by in situ hybridizationFigure 3
Detection of PC5/6 transcripts in WT and iKO intestine by in situ hybridization. Cryosections were hybridized with 
a PC5/6-specific probe, stained with cresyl violet and dipped in an autoradiography emulsion. The extent of 35S labeling was vis-
ualized on dark field.
Intestinal tumor formation in WTMin and iKOMin miceFigure 4
Intestinal tumor formation in WTMin and iKOMin mice. (A) Representative sections of WTMin and iKOMin ileum stained 
with methylene blue. Arrows point at visualized tumors. (B) Total tumor numbers and large tumor (> 2 mm) numbers in 
WTMin and iKOMin intestine of 4 month-old WTMin (n = 11) and iKOMin mice (n = 17). (C) Numbers of tumors per cm of duo-
denum, jejunum, ileum or colon in the above mice are shown. *, P < 0.05 (Student's t test)
Molecular Cancer 2009, 8:73 http://www.molecular-cancer.com/content/8/1/73Could PC5/6 specifically process a tumor-suppressor or
inactivate a tumorigenic factor, and hence act in an oppo-
site fashion to other basic aa-specific PCs? Opposing func-
tions can occur by cleavage of the same substrate at
different sites, as illustrated by the ability of furin to acti-
vate the cell adhesion molecule N-cadherin and PC5/6 to
inactivate it (Maret D. et al., submitted). In the duodenum,
PC5/6 was only 1.7-fold less abundant than furin, while
its ratio to furin was 3- to 10-fold lower in other segments
of the intestine [see Additional file 44: figure S4]. Thus,
tumorigenesis in the duodenum may depend on the bal-
ance between activation and/or inactivation of proteins
by resident furin and PC5/6, respectively. In tumors of the
duodenum, PC5/6 mRNA levels are ~ 7-fold lower than
those of furin (Figure 1C). Thus, the pro-tumorigenic
properties of furin [46] may in some cases overshadow the
protective effect of PC5/6. We surmise that within the
duodenum, furin may activate precursors implicated in
epithelial to mesenchymal transition, involved in early
tumorigenesis and invasion/metastasis [47], such as E-
cadherin [48] and TGF-β [49], while PC5/6 may inhibit
tumorigenesis, e.g., via inactivation of adhesion proteins
such as N-cadherin (Maret D. et al., submitted), resulting in
a lower number of tumors.
Conclusion
Future studies aimed to identify the implicated substrates
will require an extensive comparative analysis of ApcMin/+-
induced tumors isolated from mice lacking PC5/6, furin
or both in enterocytes. Whether the mechanism behind
the shortened survival of ApcMin/+ mice lacking PC5/6 (Fig-
ure 5) is due to more severe hemorrhages resulting from a
greater vessel fragility induced by the loss of PC5/6 [15]
would require a more detailed examination. Furthermore,
the importance of specific PCs in the invasion/metastasis
process, which is heavily regulated by adhesion molecules
processed by PCs [17,27] is yet to be fully investigated in
an appropriate in vivo model. Finally, this is the first report
that emphasizes the opposite roles of furin and PC5/6 in
tumorigenesis. Thus, recently proposed treatments aimed
to reduce furin activity [9,18-27] should include careful
monitoring of their effects on PC5/6 levels and/or activity.
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Down-regulation of PC5/6 expression in various cancers. Datasets 
were retrieved from ONCOMINE (a cancer microarray database and 
integrated data-mining platform) with a threshold of P < 0.0001. PC5/6 
expression value in tumors was log2 transformed and normalized by that 
in the adjacent normal tissue.




Decreased expression of PC5/6B, but not PC5/6A, in intestinal 
tumors versus adjacent normal tissues. Specific primers were used for 
QPCR analysis of the two PC5/6 isoforms. Normal (N) and tumoral (T) 
expression of PC5A and PC5B was assessed by using isoform-specific 
primers. Error bars represent SEM and n = 6 for each intestine section. *, 
P < 0.05 for PC5/6B (Student's t test)
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Decreased survival of ApcMin/+ mice in the absence of PC5/6Figure 5
Decreased survival of ApcMin/+ mice in the absence of 
PC5/6. Survival rates of WTMin (n = 21) and iKOMin (n = 22) 
mice were compared. P = 0.03 (Log-rank test)Page 7 of 9
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